Who
James A. Geraghty
Director
Company insider
Files Form 4 as: Director, Fulcrum Therapeutics; Director, Voyager Therapeutics; Director, Palvella Therapeutics; Director, Orchard Therapeutics; Director, Idera Pharmaceuticals; Director, Juniper Pharmaceuticals; Senior Vice President, Genzyme; Director, Gtc Biotherapeutics.
In numbers
- Trades disclosed
- 138
- Buys
- 21
- Sells
- 3
- Bought
- $1.6M
- Sold
- $2.1M
- Companies
- 8
- Companies where not an officer
- 7
- First trade
- 29 Sep 2006
- Last trade
- 30 Jun 2026
- Last filed
- 2 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 30 Jun 2026filed 2 Jul 2026 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —36,000 at $0.00 | filing |
| 3 Jun 2025filed 4 Jun 2025 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 12 Dec 2024filed 12 Dec 2024 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Code D | $01 at $0.01 | filing |
| 7 Aug 2024filed 28 Oct 2024 | PVLA Palvella TherapeuticsBiotechnology | SEC FORM 4 Bought | $11 at $1.00 | filing |
| 17 Jun 2024filed 18 Jun 2024 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 24 Jan 2024filed 24 Jan 2024 | Orchard Therapeuticsoption or derivative | SEC FORM 4 Code D | —46,000 at $0.00 | filing |
| 24 Jan 2024filed 24 Jan 2024 | Orchard Therapeuticsoption or derivative | SEC FORM 4 Code D | —105,000 at $0.00 | filing |
| 24 Jan 2024filed 24 Jan 2024 | Orchard Therapeutics | SEC FORM 4 Code D | —44,391 | filing |
| 27 Jun 2023filed 29 Jun 2023 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 21 Jun 2023filed 23 Jun 2023 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | Orchard Therapeuticsoption or derivative | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 6 Jun 2023filed 7 Jun 2023 | VYGR Voyager Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 27 Jun 2022filed 29 Jun 2022 | FULC Fulcrum Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 23 Jun 2022filed 27 Jun 2022 | Idera Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | PVLA Palvella Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
News
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) Director Sells $1,758,290.88 in StockPVLA · tickerreport.com · 17 Oct 2026Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual ConferencePVLA · manilatimes.net · 15 Oct 2026Palvella Therapeutics (NASDAQ:PVLA) Director Sells $935,202.64 in StockPVLA · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name James A. Geraghty; 3 articles from the last 14 days about the 3 companies they traded most, at most three about any one of them.